GlassScriptPhysician profile
Sherlande Raphael-Hector
NPI 1033760913
$971.35
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $691 · 2022: $280.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171.87 | 2021-2022 | |
| Medtronic, INC. | $163.02 | 2021-2022 | |
| Amgen INC. | $161.65 | 2021 | |
| Nevro Corp. | $144.79 | 2022 | |
| Collegium Pharmaceutical, INC. | $93.17 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $65.91 | 2021 | |
| Biodelivery Sciences International, INC. | $41.94 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.82 | 2021-2022 | |
| Si-Bone, INC. | $28.57 | 2021 | |
| Ibsa Pharma INC. | $17.65 | 2021 | |
| Nalu Medical, INC. | $17.05 | 2021 | |
| Merz Pharmaceuticals, LLC | $14.23 | 2021 | |
| Boston Scientific Corporation | $12.68 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherlande Raphael-Hector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.